Janus Henderson Global Life Sciences Fund Class T JAGLX

Morningstar Medalist Rating
  • NAV / 1-Day Return$95.59  /  +0.19%
  • Fund Size$6.2B
  • Adjusted Expense Ratio0.920%
  • Net Expense Ratio0.910%
  • Fee Level: DistributionAverage
  • Share Class TypeNo Load
  • Morningstar CategoryHealth
  • Equity Style Box (Funds)Large Blend
  • Minimum Initial Investment$2,500
  • Investment StatusOpen
  • TTM Yield0.32%
  • Turnover Ratio30%

Morningstar’s Analysis JAGLX

Will JAGLX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

One of our high-conviction healthcare offerings.

Senior Analyst Ramanand Kothari

Ramanand Kothari

Senior Analyst

Summary

Janus Henderson Global Life Sciences benefits from an exceptional lead manager, strong support resources, and a consistently applied robust investment process with prudent risk management, underpinning its Above Average People and Process Pillar ratings.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JAGLX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings43.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.59555M
Healthcare

Johnson & Johnson

7.76449M
Healthcare

AbbVie Inc

4.92285M
Healthcare

UnitedHealth Group Inc

4.26247M
Healthcare

AstraZeneca PLC

3.66212M
Healthcare

Thermo Fisher Scientific Inc

3.34193M
Healthcare

Novartis AG ADR

2.71157M
Healthcare

Roche Holding AG 0%

2.65153M
Corporate

argenx SE ADR

2.44141M
Healthcare

Merck & Co Inc

2.34136M
Healthcare

Sponsor Center